The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 1, 2007, Pages 65-73

  McEwen, John ^a,b   Purcell, Patrick M ^a   Hill, Richard L ^a   Calcino, Lisa J ^b   Riley, Cathy G ^b  

^a Therapeutics Goods Administration   (Australia)

^b Medicare Australia ^*  (Australia)

Author keywords

Drug utilisation; Leflunomide; Methotrexate adverse reaction reporting; Pancytopenia

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; COLESTYRAMINE; CORTICOSTEROID; DICLOFENAC; FOLIC ACID; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INDOMETACIN; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PENICILLIN G; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TENOXICAM;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE MARROW HYPOPLASIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG FEVER; DRUG MARKETING; DRUG USE; DYSPNEA; ERYTHEMA MULTIFORME; FEMALE; HUMAN; INCIDENCE; MALE; MELENA; MONOTHERAPY; PANCYTOPENIA; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SEPTICEMIA; SORE THROAT; STOMATITIS; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTIRHEUMATIC AGENTS; AUSTRALIA; CARBAMAZEPINE; CHILD; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INCIDENCE; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; ORGANOGOLD COMPOUNDS; PANCYTOPENIA; PRESCRIPTIONS, DRUG; THROMBOCYTOPENIA;

EID: 33846531248     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1236     Document Type: Article

References (27)

1. Aventis Pharma Australia. Arava product information. Approved by TGA 28 September 1999; Safety related notification 2 November 1999.
2. Commonwealth of Australia. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners 1 February 2002: 183
3. Council for International Organizations of Medical Sciences (CIOMS) 1999. Reporting Adverse Drug Reactions - Definitions of Terms and Criteria for their Use, White Blood Cell and RES (Reticulo-endothelial system) disorders (SOC 1220): 102.
4. Commonwealth of Australia. Australian Statistics on Medicines 2001-2002. Available from URL: http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/health-pbs-general-pubs-asm.htm [Accessed 2005 October 26].
5. Adverse Drug Reactions Advisory Committee. Leflunomide - serious hepatic, blood, skin and respiratory reactions. Aust Adverse Drug React Bull 2001; 20: 1.
6. Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate (letter). Ann Pharmacother 2003; 37: 149.
7. Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38: 1206-1211.
8. European Agency for the Evaluation of Medicinal Products. EMEA Public Statement on leflunomide (Arava) - Pancytopenia and serious skin reactions. 25 October 1999. Available from URL: http://www.emea.eu.int/ pdfs/human/press/pus/3163799EN.pdf [Accessed 2004 June 11].
9. Aventis Pharma Australia. Arava product information. Approved by TGA 28 September1999; Safety related notification 10 December 2001.
10. El Desoky ES. Pharmacology of rheumatoid arthritis: an overview. Curr Ther Res 2001; 62: 92-112.
11. Auer J, Hinterreiter M, Allinger S, Kirchgatterer A, Knoflach P. Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Medico Austriaca 2000; 27: 131-132.
12. Marchesoni A, Arreghini M, Panni B, Battafarano N, Uziel L. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab (letter). Rheumatology 2003; 42: 193-194.
13. Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639-644.
14. Ohosone Y, Okano Y, Kameda H, et al. Clinical characteristics related to methotrexate-induced pancytopenia (letter). Clin Rheumatol 1997; 16: 321-323.
15. Methotrexate tablets USP Faulding. In Compendium of Pharmaceuticals and Specialities (35th edn), Wellbanks L (ed). Canadian Pharmacists Association: Ottawa, 2000; 927.
16. Medical Officer Review. Leflunomide NDA 20,905 US Food and Drug Administration Center for Drug Evaluation and Research: 50. Available from URL: http://www.fda.gov/cder/foi/nda/98/20905_ARAVA_MEDR_P1.PDF [Accessed 2004 June 11].
17. Weinblatt MR, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-1328.
18. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002; 137: 726-733.
19. Cohen S, Schiff M, Weaver A, et al. Leflunomide(LEF) as initial therapy with methotrexate (MTX) added for rheumatoid arthritis patients with active disease. Arthritis Rheum 2002; 46(9): 5538.
20. Kremer J, Genovese M, Cannon GW, et al. Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis failing MTX monotherapy: an open label extension study. Arthritis Rheum 2001; 44(9): S144.
21. Boers A, Littlejohn G. Clinical experience with leflunomide in 142 rheumatoid arthritis patients. Ann Rheum Dis 2003; 62 (Suppl. 1): S39.
22. Cannon GW, Schiff M, Strand V, Holden WL. Hepatic adverse events and other toxicity during treatment with leflunomide (LEF), methotrexate(MTX), other disease-modifying antirheumatic drugs (DMARDs)and combination DMARD therapy: comparison to NSAIDs alone and adjustment for comorbidities. Arthritis Rheum 2002; 46 (Suppl. 1): S166.
23. Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. A bi-cohort study of the risks of leflunomide and other DMARDS in rheumatoid arthritis. FDA Advisory Committee Meeting Briefing Document. Appendix 5 (pages 254-291). U.S. Food and Drug Administration. March 5.2003. Available from URL: http://www.fda.gov/ohrma/dockets/ac/03/briefing/ 393930B2_01_Aventis-Arava.pdf [Accessed 2004 June 25].
24. Label/leflunomide NDA 20,905. US Food and Drug Administration Center for Drug Evaluation and Research: 10-11. Available from URL: http://www.fda.gov/cder/foi/label/1998/209051b1.pdf [Accessed 2004 June 15].
25. Label/leflunomide NDA 20-905/S-006. US Food and Drug Administration Center for Drug Evaluation and Research: 16. Available from URL: http://www.fda.gov/cder/foi/label/2003/ 20905slr007,20905se1-006_arava_lbl.pdf [Accessed 2004 June 25].
26. Martin K, Bentaberry F, Dumoulin C, et al. Prescription patterns of leflunomide in rheumatoid arthritis: clinical trials compared with actual practice. Pharmacoepidemiology Drug Safe 2004; 13: S72.
27. Van Roon EN, Jansen TLThA, Mourad L, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004; 58: 201-208.